everolimus / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

18 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
everolimus / Generic mfg.
NCT00856466: Extension Study to CRAD001A1202

Active, not recruiting
3
110
Japan
everolimus, mycophenolate mofetil
Novartis
Renal Transplant
12/12
 
REACH3, NCT03112603 / 2016-004432-38: A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation

Checkmark Data from REACH3 trial for acute GVHD at ASH 2020
Dec 2020 - Dec 2020: Data from REACH3 trial for acute GVHD at ASH 2020
Checkmark Data from REACH3 trial in steroid-refractory chronic GVHD
Jul 2020 - Jul 2020: Data from REACH3 trial in steroid-refractory chronic GVHD
Completed
3
330
Europe, Canada, Japan, US, RoW
Ruxolitinib, Jakafi, INCB018424, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Incyte Corporation
Graft-versus-host Disease (GVHD)
05/20
12/22
CLEAR trial, NCT02811861 / 2016-000916-14: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

Checkmark Presentation of data from CLEAR trial in advanced RCC at IKCS 2022
Nov 2022 - Nov 2022: Presentation of data from CLEAR trial in advanced RCC at IKCS 2022
Checkmark Data from CLEAR trial in combination with Lenvima for RCC at ESMO 2022
Sep 2022 - Sep 2022: Data from CLEAR trial in combination with Lenvima for RCC at ESMO 2022
Checkmark Data from CLEAR trial in combination with Lenvima for RCC at ASCO 2022
More
Active, not recruiting
3
1069
Europe, Canada, Japan, US, RoW
Lenvatinib, Everolimus, Pembrolizumab, Sunitinib
Eisai Inc., Merck Sharp & Dohme LLC
Renal Cell Carcinoma
08/20
07/24
CONCEPT study, NCT03095040: CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

Active, not recruiting
3
390
RoW
CM082 combined with everolimus, X-82, Affinitor, CM082, Everolimus
AnewPharma
Renal Cell Cancer Metastatic
02/21
12/21
2022-000507-12: A randomized, controlled, open-label study of RYZ101 compared with standard of care therapy in subjects with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following 177Lu SSA therapy Ensayo aleatorizado, controlado y abierto de RYZ101 frente al tratamiento habitual en sujetos con tumores neuroendocrinos gastroenteropancreáticos bien diferenciados SSTR+, avanzados e inoperables, que hayan progresado tras tratamiento con 177Lu SSA.

Not yet recruiting
3
288
Europe
RYZ101, Sunitinib, RYZ101, Sunitinib, L01XE04, Solution for injection, Tablet, Capsule, hard, Powder and solvent for suspension for injection, Solution for injection in pre-filled syringe, Everolimus Zentiva 5mg Tabletten, Szunitinib Mylan 12,5 mg, Sandostatin® LAR®- Monatsdepot 30 mg powder and solvent for suspension for injection, SOMATULINE AUTOGEL 120 mg solution for injection in a pre-filled syringe, Szunitinib Sandoz 12,5 mg
RayzeBio, Inc., RayzeBio, Inc.
gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, Diseases [C] - Cancer [C04]
 
 
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
IDUNN, NCT04629833 / 2019-001462-15: Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting
3
210
Europe
MC0518, BAT
medac GmbH
Steroid-refractory Acute Graft-versus-host Disease
12/25
12/27
ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated
3
52
Europe, US, RoW
Enobosarm, VERU-024, Exemestane, Mestane
Veru Inc.
Metastatic Breast Cancer
01/24
01/24
COMPETE, NCT03049189 / 2016-001897-13: Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Active, not recruiting
3
309
Europe, US, RoW
177Lu-edotreotide PRRT, 177Lu-DOTATOC, 177Lu-Edo, Everolimus, Afinitor, Amino-Acid Solution, Arginine-Lysine Solution
ITM Solucin GmbH, ABX CRO, PSI CRO
Neuroendocrine Tumors
12/24
12/29
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting
3
202
Europe, US, RoW
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
ITM Solucin GmbH
Neuroendocrine Tumors
06/27
09/27
ML43171, NCT05306340 / 2022-000199-20: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Recruiting
3
320
Europe, Japan, US, RoW
Giredestrant, GDC-9545, RO7197597, RG6171, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse
Genentech, Inc.
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
10/24
03/26
ACTION-1, NCT05477576: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Active, not recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus 10 mg, Sunitinib 37.5 MG, Octreotide LAR 60 MG Injection, Lanreotide 120Mg Sa Susp Inj Syringe
RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
07/25
07/28
LITESPARK-005, NCT04195750 / 2019-003444-72: A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Active, not recruiting
3
736
Europe, Canada, Japan, US, RoW
Belzutifan, MK-6482, WELIREG™, Everolimus, Afinitor, Afinitor DISPERZ, Zortress
Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
09/25
09/25
NCT06105632: A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Recruiting
3
510
Europe, Canada, Japan, US, RoW
PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane
Pfizer
Advanced or Metastatic Breast Cancer
12/25
12/28
NCT02962414 / 2016-002977-37: Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Active, not recruiting
3
206
Europe, Canada, Japan, US, RoW
everolimus, RAD001
Novartis Pharmaceuticals
Tuberous Sclerosis Complex
08/27
08/27
BIOMEDE 2, NCT05476939: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

Recruiting
3
409
Europe
Everolimus, VOTUBIA, AFINITOR, ONC201, Radiotherapy
Gustave Roussy, Cancer Campus, Grand Paris, Chimerix, Innovative Therapies For Children with Cancer Consortium
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
09/28
09/31
FRUSICA-2, NCT05522231: Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma

Recruiting
2/3
264
RoW
fruquintinib+sintilimab, HMPL-013 + IBI308, axitinib / everolimus, fruquintinib, HMPL-013
Hutchison Medipharma Limited
Advanced Renal Cell Carcinoma
11/24
03/25
STAPOVER, NCT03458221: Signal TrAnsduction Pathway Activity Analysis in OVarian cancER

Recruiting
2/3
148
Europe
Letrozole Oral Product, Bicalutamide Oral Product, Everolimus Oral Product, Itraconazole Oral Product
Gynaecologisch Oncologisch Centrum Zuid, Radboud University Medical Center, Erasmus Medical Center, Maastricht University Medical Center, InnoSIGN, Eurofins
Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation, Therapy-Associated Cancer
10/26
10/26

Download Options